Your end-to-end CDMO partner for your viral vector projects

Learn more about us

WHO ARE WE?

We are a pure play Contract Development and Manufacturing Organization (CDMO) specialized in the development and manufacturing of gene therapies, oncolytic viruses and vaccine candidates. Our teams of experts based at our 3 sites – in Europe and US – are devoted to supporting innovative projects and help reduce overall timelines and costs.

Our mission is to provide GMP viral vectors from early-stage to market, contributing to the success of our clients’ immunotherapy and gene therapy innovations.

We offer a broad range of viral vectors, including AAV, LVV, MVA, Poxvirus, Vaccinia, Measles, and more.

Our CDMO services include manufacturing of bulk drug substance, fill-finish of drug products, process and assay development, bioanalytical testing and regulatory support.

We place the client at the heart of everything we do. We implement strategies to achieve best-in-class customer experience. A team of experts is dedicated to your project to provide you with the best innovative solutions adapted to your needs.

  • 1994
    first viral vector facility in Europe
  • 3
    facilities
    (France & USA)
  • ~300
    employees
  • >25
    years of experience
    in viral vectors
    (manufacturing)
  • Fill & Finish up to
    10 000
    vials/batch

OUR HISTORY

ABL is a pure play Contract Development and Manufacturing Organization (CDMO) specialized in the development and manufacturing of oncolytic viruses, gene therapies, and vaccine candidates based on viral vectors. 

We are grounded in the Mérieux family’s legacy of biology and vaccine expertise, dating back to 1897

As a pioneer, we have been developing and producing viral vectors since the 1990s. We started with Pox Virus, MVA, Vaccinia and oncolytic viruses to support our clients’ clinical trials with the ultimate goal of fighting smallpox and several types of cancer.

We have continuously added new viruses to our portfolio, including manufacturing of AAVs in 2016 through adherent and suspension processes. Based on this strong expertise in virology and cell culture, in 2022 we decided to develop our high predictable yield and versatile AAV platform to manufacture different serotypes.

More than ever, our vision is to contribute to a long-term public health vision where Bio-Industry has a central role for a healthier world. 

1961
1968
1985
2001
2004
2011
2014
2016
2018

1961

Bionetics Research Laboratory was established

1968

Acquired by Litton Industries.
Expanded activities in retrovirus and cancer research

1985

Organon Teknika acquires R&D and diagnostic assets, renames company ABL

2001

ABL acquired by bioMérieux.
ABL becomes an Institut Mérieux Company

2004

ABL spun out from bioMérieux as a sister company, under Institut Mérieux

2011

ABL opens Rockville, MD headquarters

2014

ABL acquires Platine Pharma in Lyon and built GCLP testing labs

2016

Creation of the first ABL entity in France through the acquisition of the Transgene production asset in Strasbourg*

* Expansion of ABL capabilities through the viral vector manufacturing plant, certified GMP in 1995.

2018

Creation of the second ABL entity in France through the acquisition of the Accinov innovative platform in Lyon

ABL is fully owned by Institut Mérieux.

OUR MISSION & VISION

OUR MISSION: By accelerating our Customer’s life-saving innovations, ABL is contributing to a long-term public health vision where Bio-Industry has a central role for a healthier world.

OUR VISION: Become a leading global biomanufacturing CDMO trusted to deliver innovation and excellence. We empower people. We foster an entrepreneurial culture. We commit to sustainability.

WHAT DO WE OFFER?

ABL

Your solution provider

Please accept marketing cookies to watch this video.

OUR LEADERSHIP TEAM

Stéphanie COLLOUD

General Director ABL Europe / Chief Operating Officer

Aymeric CANU

Chief Finance Officer

Nicolas SALAVIN

Chief Technology Officer

Arnaud MARTIN

Chief Business Officer

Béatrice BARBIER

Legal / Compliance Director

Estelle AZOULAY

Human Ressources Director